TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29627147

Group type: EXPERIMENTAL
Intervention: High dose (10-50 million pfu)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Low dose (300,000 pfu)
Number of subjects: 217

Group type: COMPARATOR
Intervention: High dose vs Low dose
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Neutralising antibodies
Number of subjects: 217
Study: 29627296

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 3414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3414
Study: 29627309

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Comparator treatment
Number of subjects: 1688
Study: 29627741

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 14
Study: 29628014

Group type: EXPERIMENTAL
Intervention: Invasive candidiasis diagnosis
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Candida score
Number of subjects: 162
Study: 29628128

Group type: EXPERIMENTAL
Intervention: Baseline thrombocytopenia (mild, ≥100 and <150 × 10^9/L)
Number of subjects: 19353

Group type: EXPERIMENTAL
Intervention: Baseline thrombocytopenia (severe, <100 × 10^9/L)
Number of subjects: 19353

Group type: COMPARATOR
Intervention: Control group (normal platelet counts)
Number of subjects: 19353
Study: 29628312

Group type: EXPERIMENTAL
Intervention: ALT-803 (20 μg/kg subcutaneously once per week) in combination with nivolumab (240 mg intravenously every 14 days)
Number of subjects: 21
Study: 29628368

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29628397

Group type: EXPERIMENTAL
Intervention: Enhanced labile plasma iron (eLPI) measured in serum samples with the FeROS eLPI kit; values greater than 0.4 μmol/L considered raised eLPI.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: eLPI as a biological mediator of iron-related toxicity.
Number of subjects: 112
Study: 29628776

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 11141

Group type: EXPERIMENTAL
Intervention: Osteoarthritis
Number of subjects: 11141

Group type: COMPARATOR
Intervention: Common mental disorders
Number of subjects: 11141
Study: 29629179

Group type: EXPERIMENTAL
Intervention: Upper limb motor competence (MC)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Lower limb motor competence (MC)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Health and fitness measures
Number of subjects: 718
Study: 29629190

Group type: EXPERIMENTAL
Intervention: Antibiotic awareness activities
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Proxy indicators for detecting problematic antibiotic behaviours
Number of subjects: 4800
Study: 29630018

Group type: EXPERIMENTAL
Intervention: Any medication taken during pregnancy
Number of subjects: 9546

Group type: EXPERIMENTAL
Intervention: Any medication taken in the first trimester
Number of subjects: 9546

Group type: EXPERIMENTAL
Intervention: Polypharmacy (taking at least five medications)
Number of subjects: 9546

Group type: EXPERIMENTAL
Intervention: Medications taken during pregnancy (excluding vitamins, supplements, and vaccines)
Number of subjects: 9546

Group type: EXPERIMENTAL
Intervention: Medications taken in the first trimester (excluding vitamins, supplements, and vaccines)
Number of subjects: 9546

Group type: EXPERIMENTAL
Intervention: Gastrointestinal or antiemetic agents
Number of subjects: 9546

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 9546

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 9546
Study: 29630439

Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 165

Group type: COMPARATOR
Intervention: Td
Number of subjects: 165
Study: 29630703

Group type: EXPERIMENTAL
Intervention: Women undergoing primary PCI
Number of subjects: 8834

Group type: COMPARATOR
Intervention: Men undergoing primary PCI
Number of subjects: 8834

Group type: EXPERIMENTAL
Intervention: Women under 60 years
Number of subjects: 8834

Group type: EXPERIMENTAL
Intervention: Women aged 60 to 74 years
Number of subjects: 8834

Group type: EXPERIMENTAL
Intervention: Women over 75 years
Number of subjects: 8834

Group type: EXPERIMENTAL
Intervention: Overall relationship among sex, age category, and 30-day mortality after IPTW adjustment
Number of subjects: 8834
Study: 29631575

Group type: EXPERIMENTAL
Intervention: Salivary cotinine (n=4024)
Number of subjects: 4024

Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide (eCO) (n=2854)
Number of subjects: 4024

Group type: EXPERIMENTAL
Intervention: Cigarettes per day (CPD) (n=2706)
Number of subjects: 4024

Group type: EXPERIMENTAL
Intervention: Smoking cessation at year 5 follow-up (n=2892, 717 quitters and 2175 smokers)
Number of subjects: 4024
Study: 29631584

Group type: EXPERIMENTAL
Intervention: Circulating sex hormones (testosterone, DHEA-S, estrogen, progesterone)
Number of subjects: 187
Study: 29631615

Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cell (BMMSC) transplantation therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Antibacterial therapy
Number of subjects: 1
Study: 29631993

Group type: EXPERIMENTAL
Intervention: Personalized advice (generalized)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Personalized advice (intake-based)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Personalized advice (intake+phenotype-based)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Personalized advice (intake+phenotype+gene-based)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Behavior change techniques from dietary taxonomy
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Behavior change techniques from smoking cessation taxonomy
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Techniques excluded from the intervention
Number of subjects: 1607
Study: 29632238

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 23783

Group type: COMPARATOR
Intervention: Clopidogrel (Control)
Number of subjects: 23783

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 23783

Group type: EXPERIMENTAL
Intervention: GPI (Glycoprotein IIb/IIIa inhibitor)
Number of subjects: 23783

Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events
Number of subjects: 23783
Study: 29632533

Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine administered in two doses (30 days apart)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine
Number of subjects: 20
Study: 29632615

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 961

Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 961
Study: 29632674

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 60
Study: 29632720

Group type: EXPERIMENTAL
Intervention: PD-1 blockade (knockout or antibody blockade)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-1 overexpression and exposure to recombinant PD-L1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palliative radiotherapy and pembrolizumab
Number of subjects: 0
Study: 29632896

Group type: EXPERIMENTAL
Intervention: Innovative and community relevant interventions for improving women's access to PHC services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sites (PHCs in six communities of similar status)
Number of subjects: 0
Study: 29632895

Group type: EXPERIMENTAL
Intervention: Warrior Wellness exercise intervention (12-week supervised, facility-based exercise intervention, 3 sessions per week of multi-component exercise training targeting strength, endurance, balance, and flexibility)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 29632996

Group type: EXPERIMENTAL
Intervention: Resolved ARDS
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Confirmed ARDS
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: Confirmed severe ARDS
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Higher tidal volume on day 1 of ARDS
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Age, non-respiratory SOFA score, lower PEEP and P/F ratio, higher peak pressure and respiratory rate
Number of subjects: 2377

Group type: COMPARATOR
Intervention: pH and presence of immunosuppression or neoplasm
Number of subjects: 2377

Group type: COMPARATOR
Intervention: Day 2 ARDS reclassification
Number of subjects: 2377
Study: 29633228

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 252

Group type: COMPARATOR
Intervention: Untreated subjects
Number of subjects: 252
Study: 29633605

Group type: EXPERIMENTAL
Intervention: CD133+ cells
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MNCs
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 29633714

Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) in primary somatosensory cortex (S1)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Subset of electrodes with multimodal properties
Number of subjects: 1
Study: 29635147

Group type: EXPERIMENTAL
Intervention: Intrathecal trastuzumab (150 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intrathecal trastuzumab (60 mg or higher)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intrathecal trastuzumab
Number of subjects: 16
Study: 29635335

Group type: EXPERIMENTAL
Intervention: Nephrologist visits (1-2 visits in the previous year)
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: General practitioner visits (4 or more visits in the previous year)
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Dietician visits
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Physical and mental quality of life (QoL)
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Risk of end-stage renal disease within 5 years
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Risk profile comparison between genders
Number of subjects: 3033
Study: 29635379

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice a day
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice a day
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 29635415

Group type: EXPERIMENTAL
Intervention: PrEP (preexposure prophylaxis) offered to participants; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PrEP adherence interventions suggested; specific details not mentioned.
Number of subjects: 0
Study: 29635495

Group type: EXPERIMENTAL
Intervention: NIH Body Weight Planner (NIH BWP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pennington Biomedical Research Center Weight Loss Predictor (PBRC WLP)
Number of subjects: 0
Study: 29635496

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration <6 months
Number of subjects: 5905

Group type: EXPERIMENTAL
Intervention: Maternal BMI ≥30 kg/m2
Number of subjects: 5905

Group type: EXPERIMENTAL
Intervention: Infants weighing <2.5 kg at birth
Number of subjects: 5905

Group type: EXPERIMENTAL
Intervention: Infants weighing ≥4 kg at birth
Number of subjects: 5905
Study: 29635498

Group type: EXPERIMENTAL
Intervention: Highest quintile of total glucosinolate intake
Number of subjects: 200907

Group type: EXPERIMENTAL
Intervention: 3 major glucosinolate subtypes
Number of subjects: 200907

Group type: EXPERIMENTAL
Intervention: Total cruciferous vegetable consumption
Number of subjects: 200907
Study: 29635500

Group type: EXPERIMENTAL
Intervention: Normal-weight obesity (NWO)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Nonobese
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Preobese-obese
Number of subjects: 178
Study: 29635504

Group type: EXPERIMENTAL
Intervention: NuVal shelf nutrition labels
Number of subjects: 0
Study: 29635527

Group type: EXPERIMENTAL
Intervention: Raltegravir intensification
Number of subjects: 33
Study: 29635629

Group type: EXPERIMENTAL
Intervention: Temocillin
Number of subjects: 762

Group type: COMPARATOR
Intervention: Disc diffusion and Etest
Number of subjects: 762

Group type: COMPARATOR
Intervention: Vitek 2
Number of subjects: 762

Group type: COMPARATOR
Intervention: Routine methods for susceptibility testing
Number of subjects: 762
Study: 29635876

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy at a maintenance dose of 1.0 g/kg every 3 weeks for 52 weeks.
Number of subjects: 13
Study: 29636030

Group type: EXPERIMENTAL
Intervention: Two-stage surgical strategy (debridement-negative pressure therapy and flap coverage) with prolonged antimicrobial therapy
Number of subjects: 61
Study: 29636042

Group type: EXPERIMENTAL
Intervention: Location where the questionnaire was completed (at home or at the general practice)
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Use of insulin, having some problems with T2D self-care, coffee consumption
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1102
Study: 29636050

Group type: EXPERIMENTAL
Intervention: Lowest sex-specific quartile of pectoralis muscle area (PMA)
Number of subjects: 3705

Group type: EXPERIMENTAL
Intervention: Pectoralis muscle area (PMA)
Number of subjects: 3705

Group type: COMPARATOR
Intervention: Paravertebral erector spinae muscle area (PVMA)
Number of subjects: 3705
Study: 29636105

Group type: EXPERIMENTAL
Intervention: Customised videogame rehabilitation programme
Number of subjects: 10
Study: 29636274

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) + Belimumab (BLM)
Number of subjects: 16
Study: 29636320

Group type: EXPERIMENTAL
Intervention: Behavior intervention with smartphone-based self-monitoring
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Behavior intervention with paper diary-based self-monitoring
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 26
Study: 29636319

Group type: EXPERIMENTAL
Intervention: Text messaging alone
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Text messaging plus phone coaching
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 512
Study: 29636790

Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 2
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: WSESSSS score ≥ 8
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 3
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: APACHE II score ≥ 14
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sepsis-3 septic-shock definition combined with WSESSSS ≥ 8
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CPIRO score ≥ 3
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 4 and WSESSSS ≥ 8 with or without septic-shock
Number of subjects: 93
Study: 29636983

Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening and core stabilization program (10 sessions, twice a week for 6 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening and core stabilization program
Number of subjects: 20
Study: 29636984

Group type: EXPERIMENTAL
Intervention: Daily protein supplement (120 mmol of solutes, allowing an extra 163 mL free water loss) for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily protein supplement
Number of subjects: 40
Study: 29637088

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 978

Group type: COMPARATOR
Intervention: Intravenous antibiotics (minimum 12 hours) followed by oral antibiotics (total course 10 days)
Number of subjects: 978
Study: 29637195

Group type: EXPERIMENTAL
Intervention: SEID-positive group (n=45)
Number of subjects: 120

Group type: COMPARATOR
Intervention: SEID-negative group (n=69)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SEID-positive and SEID-negative groups
Number of subjects: 120
Study: 29637198

Group type: EXPERIMENTAL
Intervention: Whole-body cooling using a low-cost servo-controlled device (set core temperature 33.5°C) for 72 hours, followed by passive rewarming.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Whole-body cooling using a low-cost servo-controlled device.
Number of subjects: 82
Study: 29637481

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29638161

Group type: EXPERIMENTAL
Intervention: High Insulin Studies (HISs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low Insulin Studies (LISs)
Number of subjects: 11
Study: 29638206

Group type: EXPERIMENTAL
Intervention: 28-IFN response gene scoring system using NanoString technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 28-IFN response gene scoring system
Number of subjects: 0
Study: 29641297

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg on a 2/1 schedule
Number of subjects: 60
Study: 29641374

Group type: EXPERIMENTAL
Intervention: Medication monitoring sensors
Number of subjects: 0
Study: 29642909

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to poor metabolizers (PMs)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to intermediate metabolizers (IMs)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to patients without a nonfunctional allele
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to non-ACS patients
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to ACS patients
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to PMs at 6 months
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to IMs at 6 months
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Clopidogrel prescribed to patients without a nonfunctional allele at 6 months
Number of subjects: 931
Study: 29642921

Group type: EXPERIMENTAL
Intervention: Robot-based perturbed-balance training (30 sessions on an instrumented treadmill with BAR-TM delivering random pushes)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control participant (no specific intervention mentioned)
Number of subjects: 2
Study: 29643053

Group type: EXPERIMENTAL
Intervention: Mobile app intervention with daily questionnaires
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Mobile app intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no mobile app)
Number of subjects: 190
Study: 29643063

Group type: EXPERIMENTAL
Intervention: Prexasertib, a Checkpoint Kinase 1 Inhibitor
Number of subjects: 0
Study: 29643170

Group type: EXPERIMENTAL
Intervention: Standard of Care surgical approach for iSGS
Number of subjects: 0
Study: 29643258

Group type: EXPERIMENTAL
Intervention: VASCOG criteria for diagnosis of mild and major NCD
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standardized battery from the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network
Number of subjects: 404
Study: 29643830

Group type: EXPERIMENTAL
Intervention: StrokeVision app-based assessment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional bedside testing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional bedside testing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gold standard testing
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual screening practice
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: StrokeVision digital assessment
Number of subjects: 48
Study: 29643928

Group type: EXPERIMENTAL
Intervention: Low energy diet (LED) for eight weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 85
Study: 29645077

Group type: EXPERIMENTAL
Intervention: Risk model for predicting colorectal cancer (CRC) based on clinical characteristics including rectal bleeding, weight loss, and changes in bowel habits.
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Risk model for predicting CRC.
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Combination of rectal bleeding with weight loss and changes in bowel habits.
Number of subjects: 362
Study: 29649002

Group type: EXPERIMENTAL
Intervention: Baricitinib treatment
Number of subjects: 18
Study: 29649027

Group type: EXPERIMENTAL
Intervention: ICU opioid exposure
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Persistent pain symptoms
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Pain intensity score
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Pain interference with daily life
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Overall pain interference score
Number of subjects: 295
Study: 29649055

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 212
Study: 29649137

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29649539

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 1618

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 1618
Study: 29649853

Group type: EXPERIMENTAL
Intervention: p.N215S males
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: p.N215S females
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: p.N215S patients
Number of subjects: 125

Group type: COMPARATOR
Intervention: classic Fabry patients
Number of subjects: 125
Study: 29649885

Group type: EXPERIMENTAL
Intervention: S-amlodipine 2.5 mg/d
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: S-amlodipine 5 mg/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Previous antihypertensive medications
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 33
Study: 29649953

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Years with HIV/AIDS
Number of subjects: 206
Study: 29649998

Group type: EXPERIMENTAL
Intervention: Nerve Conduction Studies (NCS)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 115
Study: 29650001

Group type: EXPERIMENTAL
Intervention: Urodynamic investigation with continuous cardiovascular monitoring
Number of subjects: 300
Study: 29650056

Group type: EXPERIMENTAL
Intervention: Prophylactic wrapping of the GDA stump using the pedicled falciform ligament
Number of subjects: 400

Group type: COMPARATOR
Intervention: No wrap
Number of subjects: 400
Study: 29650119

Group type: EXPERIMENTAL
Intervention: Ajmaline testing (1 mg/kg/5 min)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Electrophysiological study and substrate mapping or ablation
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Substrate ablation
Number of subjects: 191